SynthesisBMC infectious diseases2020
Safety and effectiveness of acellular pertussis vaccination during pregnancy: a systematic review.
Synthesis in BMC infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 3 syntheses or guidelines pooled it, 167 citations in OpenAlex.
- Transplacental transfer of anti-malarial antibodies: a systematic review.Frontiers in immunology · 2026Pooled it
- Are maternal vaccines effective and safe for mothers and infants? A systematic review and meta-analysis of randomised controlled trials.BMJ global health · 2023Pooled it
- The association between vaccine hesitancy and pertussis: a systematic review and meta-analysis.Italian journal of pediatrics · 2023Pooled it
- Trial
- Article
- [Use of vaccines to prevent the development of bacterial resistance].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2026Review
- The Effect of Maternal Pertussis Vaccination on Neonatal Health Outcomes in the Dutch Pregnancy Drug Register.Birth defects research · 2026Article
- Coadministered Influenza- and Pertussis-Containing Vaccines in Pregnant Women.JAMA network open · 2026Article
- Improved pertussis vaccine uptake following in-hospital administration among pregnant women living with HIV.Archives of gynecology and obstetrics · 2026Observational
- Maternal Vaccine Receipt and Infant Hospital and Emergency Visits for Influenza and Pertussis.JAMA network open · 2026Article
- Post-marketing safety surveillance of tetanus, diphtheria, and acellular pertussis (Tdap) vaccine: a disproportionality analysis of the vaccine adverse event reporting system (2015-2025).Frontiers in cellular and infection microbiology · 2026Article
- Knowledge, Attitude, and Intention to Receive the Pertussis Vaccine in Pregnant Women: A Systematic Review.Healthcare (Basel, Switzerland) · 2025Review
- Are Online Maps and Booking Systems for Antenatal Vaccination Fit for Purpose? A Qualitative Study.Vaccines · 2025Article
- Influencing Factors of Pregnant Women's Willingness to Receive Influenza Vaccination in China.Vaccines · 2025Article
- Quantifying maternal vaccination opportunities across gestational age windows: a real-world multi-country, longitudinal study.AJOG global reports · 2025Article
- Vaccination in pregnancy to protect the newborn.Nature reviews. Immunology · 2025Review
- Clinical and Epidemiological Characteristics of Pediatric Pertussis Cases: A Retrospective Study from Southeast Romania.Antibiotics (Basel, Switzerland) · 2025Article
- Systematic review and meta-analysis of interventions to increase the uptake of vaccines recommended during pregnancy.NPJ vaccines · 2025Article
- Review
- Uptake of Recommended Vaccines During Pregnancy Among Publicly and Privately Insured People in the United States, December 2020-September 2022.American journal of public health · 2025Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInfants < 3 months of age are at highest risk for developing severe complications after pertussis. The majority of pregnant women has low concentrations of pertussis-specific antibodies and thus newborns are insufficiently protected by maternally transferred antibodies. Acellular pertussis vaccination during pregnancy was recently implemented in various countries. Here, we assessed the evidence for safety and effectiveness of pertussis vaccination during pregnancy.
methodsWe searched Medline, Embase, and ClinicalTrials.gov from January 1st 2010 to January 10th 2019. We assessed risk of bias (ROB) using the Cochrane ROB tool and ROBINS-I. We evaluated the quality of evidence using the GRADE approach.
resultsWe identified 1273 articles and included 22 studies (14 for safety; 8 for effectiveness), comprising 1.4 million pregnant women in safety studies and 855,546 mother-infant-pairs in effectiveness studies. No significant differences between vaccinated and unvaccinated women and their infants were observed for safety outcomes with the exception of fever and chorioamnionitis. Compared to no vaccination, three studies showed a significantly increased relative risk for the presence of the ICD-9 code for chorioamnionitis in electronic patient data after pertussis vaccination. However, no study reported an increased risk for clinical sequelae of chorioamnionitis after vaccination during pregnancy, such as preterm birth or neonatal intensive care unit admission. Vaccine effectiveness against pertussis in infants of immunized mothers ranged from 69 to 91% for pertussis prevention, from 91 to 94% for prevention of hospitalization and was 95% for prevention of death due to pertussis. Risk of bias was serious to critical for safety outcomes and moderate to serious for effectiveness outcomes. GRADE evidence quality was moderate to very low, depending on outcome.
conclusionAlthough an increased risk for a diagnosis of fever and chorioamnionitis was detected in pregnant women after pertussis vaccination, there was no association with a higher frequency of clinically relevant sequelae. Vaccine effectiveness for prevention of infant pertussis, hospitalization and death is high. Pertussis vaccination during pregnancy has an overall positive benefit-risk ratio. In view of the overall quality of available evidence ongoing surveillance of chorioamnionitis and its potential sequelae is recommended when pertussis vaccination in pregnancy is implemented.
trial registrationPROSPERO CRD42018087814, CRD42018090357.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.